SCHEMBL9945668

SCHEMBL9945668

CCCCCCCCCc1ccc(C(C)N)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.60
ESR1 P03372 2/20 0.55
ADRA2A P08913 2/20 0.55
ADORA3 P0DMS8 2/20 0.55
TACR2 P21452 2/20 0.55
SLC6A2 P23975 2/20 0.55
SLC6A4 P31645 2/20 0.55
SLC6A3 Q01959 2/20 0.55
KDM4E B2RXH2 1/20 0.55
ALDH1A1 P00352 1/20 0.55
LMNA P02545 1/20 0.55
SHBG P04278 1/20 0.55
TP53 P04637 1/20 0.55
CYP3A4 P08684 1/20 0.55
HSPD1 P10809 1/20 0.55
ADRB3 P13945 1/20 0.55
HTR2C P28335 1/20 0.55
HSPE1 P61604 1/20 0.55
HIF1A Q16665 1/20 0.55
TST Q16762 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1313200 1.00 HTR2A (0.60) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL1009348 1.00 HTR2A (0.60) HTR2AESR1ADRA2AADORA3TACR2
Hydrochloric Acid SCHEMBL11737570 0.98 HTR2A (0.58) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL19174795 0.98 HTR2A (0.57) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL29342921 0.92 HTR2A (0.50) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL11686889 0.92 HTR2A (0.50) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL29342569 0.92 HTR2A (0.50) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL30469503 0.86 HTR2A (0.62) HTR2AESR1ADRA2AADORA3TACR2
SCHEMBL6861225 0.86 HTR2A (0.62) HTR2AESR1ADRA2AADORA3TACR2
Hydrochloric Acid SCHEMBL27998571 0.86 HTR2A (0.62) HTR2AESR1ADRA2AADORA3TACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120148530-A1 Method for the treatment or prevention of virus infection using polybiguanide-based compounds NOVAFLUX BIOSCIENCES, INC. (US) 2012-06-14 US disclosed
US-20110275673-A1 INHIBITORS OF SPHINGOSINE KINASE 1 GENZYME CORPORATION 2011-11-10 US disclosed
US-20110275673-A1 INHIBITORS OF SPHINGOSINE KINASE 1 GENZYME CORPORATION 2011-11-10 US disclosed
US-7772284-B2 Method for the treatment or prevention of virus infection using polybiguanide-based compounds NOVAFLUX INC. 2010-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275673-A1 INHIBITORS OF SPHINGOSINE KINASE 1 SPHK1, SPHK2, S1PR1 HTR2A 4137/4885ESR1 4317/4885ADRA2A 2758/4885
US-20120148530-A1 Method for the treatment or prevention of virus infection using polybiguanide-based compounds SAMHD1, TK1, SORD HTR2A 4878/4885ESR1 3740/4885ADRA2A 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.